Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

BACKGROUND: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol Rep
Autors principals: Pelligra, Silvia, Buza, Natalia, Hui, Pei, Bellone, Stefania, Zeybek, Burak, Ratner, Elena, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049633/
https://ncbi.nlm.nih.gov/pubmed/32140533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2020.100554
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars